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for combination chemotherapy resistance 
detection of colon adenocarcinoma
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Abstract 
Background and objectives: Colon cancer is a frequently occurring primary malignant tumor. Chemotherapy can 
reduce the risk of local and distant relapse. Therefore, it is very important to find new biomarkers that can predict 
chemoresistance and help in individuate treatment decision.
Design and setting: Retrospective analysis of 126 patients, who were treated at our department between June 2010 
and December 2014.
Patients and methods: In this study, we examined the expression levels of 1200 human miRNAs in colon cancer 
tissues, using laser capture microdissection and microRNA profiling arrays. A validation study was done to corrobo-
rate a subset of the results, including expression levels of miR-4299, miR-196b, miR-324-5p, miR-455-3p and miR-939, 
through analyzing stage IV colon adenocarcinoma tissues (not responding and responding to the chemotherapy) 
with laser capture microdissection and quantitative real-time PCR. We analyze the relationship between the expres-
sion levels of these miRNAs and the survival rate of colon cancer patients by Kaplan–Meier method.
Results: We found that miR-4299 and -196b have significant diagnostic value in chemoresistant colon cancer. MiR-
4299 yielded an AUC (the areas under the ROC curve) of 0.810 and miR-196b yielded an AUC of 0.726 in discriminat-
ing chemoresistant colon cancer from controls. Combined with ROC analyses of these 2 miRNAs revealed an elevated 
AUC of 0.877 with 71.4 % sensitivity and 95.5 % specificity in discriminating chemoresistant colon cancer. The low 
level of miR-4299 expression and the high level of -196b expression are significantly correlated with better survival of 
colon cancer patients.
Discussion: These data suggest that miR-4299 and -196b have strong potential as novel biomarkers for chemoresist-
ance detection of colon cancer.
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Background
Colon cancer is one of the most frequent cancers and a 
common cause of cancer-related deaths [1]. Due to the 
poor prognosis and distant invasion and migration, the 
overall incidence of colon cancer is approximately 5  % 
and the 5-year survival rate of colon cancer patients is 
very low [2]. In China, the morbidity and mortality of 
colon cancer are 14.68/105 and 6.66/105, which is faster 
than the average increasing rate of the world. In Shang-
hai, the incidence of colon cancer is one of the highest in 
china (25.55/105) [3]. Thus, the identification of new tar-
gets for the development of predicted chemoresistance is 
urgent in colon cancer patients.
MicroRNAs (miRNAs) are small, noncoding 
sequences, approximately 18–25 nucleotides long, which 
are post-transcriptional regulators of gene expression. 
They use imperfect base-pairing with the 3′-untranslated 
region (3′ UTR) of messenger (m) RNA, usually resulting 
in translational repression and gene silencing. Aberrant 
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expression of miRNAs is implicated in numerous dis-
eases and miRNA misregulation is also linked to many 
types of cancer [4, 5]. Depending on the genes miRNAs 
are regulated; miRNAs can function as either oncogenes 
or tumor suppressors [6].
After the discovery, that the miRNAs are involved in 
a significant number of biological processes, such as 
development, differentiation, apoptosis and prolifera-
tion, it became evident that miRNAs are widely involved 
in the initiation and progression of cancer. [7, 8] Micro-
RNAs are able to control protein expression. It has been 
suggested that modification of miRNA gene expression 
could be an important factor in the response to drug 
treatment [9].
The median progression-free survival of advanced 
colorectal cancer (CRC) patients has increased since the 
introduction of oxaliplatin in combination with 5-fluo-
rouracilin systemic chemotherapy treatment [10]. How-
ever, colorectal cancer is resistant to chemotherapy and 
chemotherapy has been less effective against transform-
ing cancerous cells in many patients, ultimately leading to 
the death of patients.
In a clinical context, Hansen found low expression of 
miR-126 in vessel structures of primary tumors associ-
ated with poor response to first-line XELOX therapy [11]. 
Further knowledge about the molecular mechanisms 
underpinning colon cancer chemoresistance may pro-
vide insights for better therapeutic opportunities to treat 
colon cancer patients. The aim of this study is to iden-
tify miRNAs that might be diagnostic and prognostic for 
chemoresistant colon cancer in relation to first-line treat-
ment with capecitabine and oxaliplatin (XELOX).
Methods
Patients
The patients were recruited in this study. Patients were 
excluded from the study if they had a clinical diagnosis 
of hereditary nonpolyposis colon cancer, or if they had 
undergone chemotherapy or radiotherapy for a diag-
nosis of cancer at any site and any time before surgery. 
All patients underwent colorectal resection; however, 
at the same time the metastases (liver or lung) were not 
surgically removed. Tumors were staged according to 
the tumor node metastasis (TNM) staging system of the 
Union for International Cancer Control (UICC). The 
study included 126 patients with colon cancer histo-
logically verified at the department of clinical pathology, 
Shanghai Cancer Center (Table  1). The patients under-
went surgery in the period from June 2010 to December 
2014. After surgery they received first-line chemotherapy. 
Pre-treatment examination consisted of standard hema-
tologic parameters (blood routine, hepatic function, renal 
function, electrolytes and so on) and a CT scan of the 
chest and abdomen and ultrasound of the abdomen. All 
patients received a minimum three cycles of XELOX.
All patients received the same treatment (XELOX), 
which consisted of a 2-h intravenous infusion of oxali-
platin 130 mg/m2 on day 1 followed by oral capecitabine 
1000  mg/m2 twice daily on days 1–14 (28 doses) of a 
21-days cycle. Treatment was continued until disease 
progression or unacceptable toxicity.
Informed consent was obtained from all participants 
for the use of their tissue samples in this study. This pro-
ject was approved by the Clinical Research Ethics Com-
mittee of Fudan University Cancer Hospital.
Table 1 Clinicopathological factors
subserosa (ss), penetration of serosa (se), and invasion of adjacent
structures (si), * P < 0.05
Factors Non-responders % Responders % P value
n = 62 n = 64
Number Number
Age [mean (SD)] 54.3 (9.1) 57.0 (12.5) 0.713
Sex 0.472
 Male 34 54.8 31 48.4
 Female 28 45.2 33 51.6
Histology
 Adenocarcinoma All All
Histological grade 0.485
 Well No No
 Moderately 32 51.6 37 57.8
 Poorly 30 48.4 27 42.2
Depth of tumor invasion
 ss, se, si All All
Lymph node metastasis 0.292
 ≤3 33 53.2 40 62.5
 >3 29 46.8 24 37.5
Venous invasion 0.383
 Absent 35 56.5 41 64.1
 Present 27 43.5 23 35.9
Nerve invasive 0.001*
 Absent 39 62.9 21 32.8
 Present 23 37.1 43 67.2
Liver metastasis 0.637
 Absent 17 27.4 20 31.3
 Present 45 72.6 44 68.7
Lung metastasis 0.248
 Absent 50 80.6 46 71.9
 Present 12 19.4 18 28.1
Tumor location 0.072
 Distal colon 38 61.3 29 45.3
 Proximal colon 24 38.7 35 54.7
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Clinical evaluation of response criteria
Treatment response, according to RECIST (version 
1. 0), was assessed every 9  weeks with clinical and 
radiologic examination using CT scan of the chest 
and abdomen (90 patients). Responding patients were 
classified as having either complete response (CR) 
or partial response (PR). Patients with stable disease 
(SD) or progressive disease (PD) were defined as non-
responders. All CT scans were evaluated by the same 
investigator.
Tissue processing
Fresh biopsies of colon tumors were collected between 
June 2010 and December 2014 during staging surgery 
(colon resection) at Shanghai Cancer Center, frozen 
within 5  min in liquid nitrogen, and stored at −80  °C. 
Investigators performing microRNA analysis were 
blinded to the clinical outcome of patients.
Laser capture microdissection, RNA extraction and miRNA 
expression profiling
Colon cancer tissues were collected by laser cap-
ture microdissection (LCM) as previously described 
[12]. Briefly, colon cancer tissues were dissected in 
1  ×  0.5  cm, and frozen in optimal cutting tempera-
ture compound (OCT) with 25  % sucrose. Sections 
were cut at 10 μm, mounted onto slides with charged 
PEN-foil membranes (Leica Microsystems, Deerfield, 
IL, USA), fixed in 100  % ice-cold ethanol for 10  min, 
stained with hematoxylin for 1 min, and dehydrated in 
100  % ethanol for 30  s and xylene for 5  min. Tissues 
of colon cell layer were isolated separately using an 
LMD6000 laser capture microdissection microscope 
(Leica Microsystems).
Total RNA isolation was performed using mirvana 
miRNA Isolation kit (Ambion, USA) according to the 
manufacturer’s protocol. RNA concentrations were 
measured using the NanoDrop ND-1000 spectropho-
tometer (Wilmington, USA). MiRNA expression pro-
files of CRCs were determined with Agilent human 
miRNA v162.0 (Santa Clara, USA). Expression lev-
els were normalized against endogenous U6 control. 
Each slide was hybridized with 100  ng Cy3-labeled 
RNA using miRNA complete Labeling and Hyb kit 
(Santa Clara, USA) according to the manufacturer’s 
instructions. After hybridization, slides were washed 
in staining dishes (Thermo Shandon, USA) with Gene 
Expression Wash Buffer Kit (Santa Clara, USA). Slides 
were scanned by Agilent Microarry Scanner (Santa 
Clara, USA) and Feature Extraction software 10.7 
(Santa Clara, USA) with default settings. Raw data were 
normalized by Quantile algorithm, Gene Spring Soft-
ware 11.0 (Santa Clara, USA).
Real-time PCR quantification of the miRNA
For the individual assay, the expression levels of mature 
miRNAs were determined by real-time quantitative 
polymerase chain reaction (q-PCR). Reverse transcrip-
tion (RT) followed by real-time PCR amplification with 
Universal cDNA synthesis kit (EXIQON, Denmark). The 
experimental procedures were done according to the 
protocol recommended by the manufacturer. Quantita-
tive real-time PCR was performed using the Power SYBR 
Green Master Mix (EXIQON, Denmark) on the 7900HT 
Real-time PCR System (Applied Biosystems). All data 
values were normalized by Human U6. The threshold 
cycle data were determined using the default threshold 
settings. All real-time PCR reactions were run in tripli-
cate and average Ct and SD values were calculated.
Statistical analysis
Clinicopathological factors were compared using X2 test 
or T test. Expression levels of tissue miRNAs were com-
pared using the Mann–Whitney U test or the Kruskall–
Wallis test. Receiver operating characteristics (ROC) 
curves were established to evaluate the diagnostic value 
of tissue miRNAs for differentiating between non-
responder and responder. Overall survival was estimated 
using the Kaplan–Meier method. A p value of less than 
0.05 was considered statistically significant. All statistical 
analysis was performed with SPSS 19.0 software (SPSS, 
Inc., Chicago, IL, USA).
Results
Patient population
A total of 126 participants including 62 colon cancer 
patients of non-responders and 64 colon cancer patients 
of responders were recruited into this study (Table 1). No 
significant differences of age, gender, histological grade, 
lymph node metastasis, venous invasion, liver metas-
tasis, lungs metastasis and tumor location were found 
between non-responder and responder, but there were 
significant differences of nerve invasive in the colon 
cancer(P  =  0.001). All patients were followed up until 
death or the end of the study.
Expression profiles of miRNAs correlated to colon cancer 
chemoresistance
To investigate the roles of miRNA in colon cancer chem-
oresistance, we first examined the miRNA expression 
profiles with Agilent Human MicroRNA Array (Among 
the 1367 unique miRNA probes) on 4 responder colon 
cancer and 4 non-responder colon cancer to the chem-
otherapy. After normalization with the endogenous 
control U6, we found that 5 miRNAs were significantly 
dysregulated in responder as compared with non-
responder (P < 0.05, paired t test) (Fig. 1a, b; Table 2). The 
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Fig. 1 Dysregulation of miRNA in human colon cancer. The miRNA profiling analysis on 4 pairs of colon cancer tissue. miRNA expression was 
normalized against endogenous control U6. a Volcano plot illustrating the biological and statistical significances of differential miRNA expressions 
between non-responders and responders in human colon cancer. miRNAs that were significantly expressed in human colon cancer are marked in 
red. b Heat map diagram generated by unsupervised clustering analysis with 5 significantly dysregulated miRNAs in their human colon cancers. 
miRNA expression profile effectively segregated non-responder samples from their corresponding responder samples
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miRNA profiling data indicate that miRNAs frequently 
were dysregulated in human colon cancer. Comparing 
among the group between non-responder and responder, 
miR-4299 and -939 were the most up-regulated and miR-
196b, miR-324-5p and 455-3p were the most down-regu-
lated miRNAs. We therefore need to further investigate 5 
miRNAs.
Differential overexpression of miR-4299 and -196b in the 
colon cancer
To evaluate the correlation between these candidates, we 
examined the expression of miR-196b, -4299, -324-5p, 
-455-3p and -939 in a panel of 126 malignant colon can-
cer tissues, including 62 non-responders and 64 respond-
ers, by individual real-time PCR. MiR-4299 and -196b 
were significantly non-responder relative to responder 
colon cancer patient (P  <  0.001 and P  =  0.021), when 
compared with the U6 control, as shown in Fig.  2. No 
significant difference was observed in the levels of miR-
324-5p, -455-3p and -939 between non-responder colon 
cancer patients and controls (P = 0.319 for miR-324-5p, 
P = 0.501 for miR-455-3p, P = 0.634 for miR-939). Taken 
together, our results determined that expression levels 
of miR-4299 were definitively higher in non-responder 
compared with responder and the expression levels of 
miR-196b were definitively lower. This suggests that they 
could be relevant to the chemoresistance of colon cancer.
The diagnostic value of miR-4299 and -196b for the 
chemoresistance of colon cancer
To test the diagnostic value of miR-4299 and -196b 
in the chemoresistance of colon cancer, we measured 
the expression of these miRNAs in tissue samples of 
62 non-responders, and found a significant expression 
when compared to the responders (p  <  0.001 for miR-
4299, P  =  0.021 for miR-196b). ROC curve analyses 
also showed that both of the 2 miRNAs could differen-
tiate non-responders from controls of responders with 
an AUC of 0.810 for miR-4299 (95  % CI 0.704–0.917) 
and 0.726 for miR-196b (95  % CI 0.597–0.856), respec-
tively (Fig. 3a, b). At the cutoff value of 1.46 for miR-4299, 
the sensitivity and the specificity were 75.0 and 88.6  %, 
respectively. At the cutoff value of 9.54 for miR-196b, 
the sensitivity and the specificity were 71.4 and 77.3  %, 
respectively. Combination ROC analyses also revealed a 
little increased AUC value of 0.877 (95 % CI 0.793–0.962) 
with 71.4 % sensitivity and 95.5 % specificity (Fig. 3c).
Under- and over-expression of miR-4299 and -196b 
expression correlated with better survival in stage IV colon 
cancer patients
To evaluate the clinical implications of the miRNAs iden-
tified in this study, we analyzed the clinical data from 126 
stage IV colon cancer patients (62 non-responders and 64 
responders) whose samples were tested in the validation 
experiment. The correlation between expression levels 
of miRNAs and overall survival were measured through 
Kaplan–Meier survival curve analysis with compari-
son using a binomial variable of high or low expression 
relative to the cutoff values of the miRNAs in the ROC 
curve analyses. Statistically significant correlation was 
observed between the overall survival and the expression 
levels of miR-4299 and miR-196b (Fig. 4a, b; P = 0.000, 
P = 0.006). According to miR-4299 and miR-196b values, 
the median OS were 18.7 (miR-4299, CI 17.4–20.0) and 
18.0 (miR-196a, CI 15.1–20.9). Collectively, the finding 
suggests that miR-4299 and miR-196b expression may 
play an important role in colon cancer chemotherapy 
prognosis.
Discussion
Surgery is the most effective treatment for colon can-
cer. However, in locally advanced stages, radiotherapy 
and chemotherapy reduces the risk of local and distant 
relapse. Consequently, a multidisciplinary approach is 
currently the standard. complete pathologic disappear-
ance of tumor cells after neoadjuvant chemotherapy 
occurs in about 20 % of patients and is correlated with a 
very good long-term prognosis. In the era of customized 
treatment, we should explore new identifiable predictive 
factors for conventional treatments, such as chemother-
apy. The ultimate goal is to select the most effective and 
less toxic treatment for every patient.
Recent studies have implicated miRNAs in a variety of 
human cancers, and their expression signatures can pro-
vide insight into the diagnosis and prognosis of human 
cancers [13–20]. At first, this study provides the report 
of quantitative global miRNA expression profiles includ-
ing expression data for 1200 human miRNAs in stage 
IV colon adenocarcinoma from clinical tissue samples. 
Then these tissue samples were mated to sex, age, histol-
ogy, histological grade, tumor location and metastasis 
location. It has been reported that miRNA expression 
profiles reflect cellular differentiation and distinguish 
tumors of different developmental origin [21, 22]. Our 
Table 2 Significant dysregulation of  miRNAs in  chemore-
sistant colon cancer
hsa human
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study revealed significant differences between the expres-
sion levels of 5 miRNAs in the sets of 8 non-responders 
and control. Secondly, in most of miRNAs we identi-
fied (miR-196b, miR-4299, miR-324-5p, miR-455-3p and 
miR-939), the potential linkage between their expres-
sion and chemoresistance was already established; then 
some of them were identified for the first time. Further-
more, we showed that miR-4299 and -196b are strongly 
regulated in non-responder colon cancer. Therefore, the 
mechanisms obtained in this study need to be further 
validated in more detailed models and on an independent 
set of patients, before applying in clinical practice.
In this study, we found that the levels of miR-4299 and 
-196b in tissue samples from non-responders were signifi-
cantly expressed than those in responders. Both miR-4299 
and -196b had significant diagnostic value for colon cancer 
and yielded AUC of 0.810 and 0.726, respectively. Combined 
ROC analyses using these 2 targets could yield an increased 
AUC of 0.877 with 71.4 % sensitivity and 95.5 % specificity 
in discriminating non-responder from responder control. 
Fig. 2 Dots indicate of the relative quantification (RQ) values of miRNA expression levels (a miR-4299, b miR-196b, c miR-324-5p, d miR-455-3p, 
e miR-939), normalized by U6. The line represents the median value. Mann–Whitney U test was used to determine statistical significance
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These suggest their potential value for early detection of 
chemoresistant colon cancer before we can initiate chemo-
therapy. To our knowledge, it is the first report to evaluate 
the diagnostic value of miRNAs on assessment of colon 
cancer resistant to first-line chemotherapy. The under- and 
over-expression of miR-4299 and -196b are significantly 
correlated with better survival of colon cancer patients.
Currently, miR-4299 is no more related research. 
MiR-196 is a negative regulator of several HOX genes. 
MiR-196 recognizes HOX mRNA with a nearly perfect 
match and cleaves the HOXB8 mRNA directly [23]. The 
importance of HOX gene expression for A-P patterning 
has been well characterized in developing limbs and the 
central axis [24]. Therefore, elevation of the expression 
of miR-196 in human cells may correlate with several 
phenotypes observed during developmental stages. MiR-
196b can be assigned with the tumor suppressor func-
tion in acute lymphoblastic leukemia [25, 26]. Plummer 
reported miR-196b is responsive to vascular endothelial 
growth factor (VEGF) stimulation, thus miR-196b may 
constitute a novel strategy for inhibiting tumor angio-
genesis [27]. Popovic reported that miR-196b function 
is necessary for MLL fusion-mediated immortalization 
and that overexpression of miR-196b increases the pro-
liferation and survival of normal bone marrow hemat-
opoietic progenitor cells [28]. Tsaithe et al. reported that 
high frequency of miR-196b promoter hypomethylation 
found in gastric cancer, miR-196b overexpression could 
provide a useful tumor marker [29]. Guan results sug-
gest that miR-196b may play a role in the malignant 
Fig. 3 Receiver operating characteristics (ROC) curve analysis using miR-4299 and miR-196b for discriminating chemoresistance of colon tumors. 
miR-4299 yielded an AUC (the areas under the ROC curve) of 0.810 (95 % CI 0.704–0.917) with 75.0 % sensitivity and 88.6 % specificity in discrimi-
nating non-responder (a), and miR-196b yielded AUC of 0.726 for miR-196b (95 % CI 0.597–0.856) with 71.4 % sensitivity and 77.3 % specificity in 
discriminating non-responder (b). Combined ROC analyses revealed an elevated AUC of 0.877 (95 % CI 0.793–0.962) with 71.4 % sensitivity and 
95.5 % specificity in discriminating non-responder (c)
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progression of gliomas and may be a prognostic predic-
tor in glioblastomas [30]. Lakomy reported miR-196b to 
be associated with survival of glioblastoma multiforme. 
MiR-196b was shown a positive correlation with OS [31].
In conclusion, miR-4299 and -196b appear to be novel 
biomarkers for detection of chemoresistant colon cancer. 
Our data serve as basis for further investigation, prefer-
ably in large prospective studies before these 2 miRNAs 
can be used as a screening tool for the treatment of colon 
cancer in routine clinical practice.
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